HUE061273T2 - Immunogén készítmény - Google Patents

Immunogén készítmény

Info

Publication number
HUE061273T2
HUE061273T2 HUE19159001A HUE19159001A HUE061273T2 HU E061273 T2 HUE061273 T2 HU E061273T2 HU E19159001 A HUE19159001 A HU E19159001A HU E19159001 A HUE19159001 A HU E19159001A HU E061273 T2 HUE061273 T2 HU E061273T2
Authority
HU
Hungary
Prior art keywords
immunogenic preparation
immunogenic
preparation
Prior art date
Application number
HUE19159001A
Other languages
English (en)
Hungarian (hu)
Inventor
Dominique Boutriau
Sophie Marie Jeanne Valentine Germain
Hugues Wallemacq
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of HUE061273T2 publication Critical patent/HUE061273T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
HUE19159001A 2012-12-05 2013-12-03 Immunogén készítmény HUE061273T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201221875 2012-12-05

Publications (1)

Publication Number Publication Date
HUE061273T2 true HUE061273T2 (hu) 2023-06-28

Family

ID=49724573

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE19159001A HUE061273T2 (hu) 2012-12-05 2013-12-03 Immunogén készítmény
HUE13801540A HUE043091T2 (hu) 2012-12-05 2013-12-03 Immunogén készítmény

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE13801540A HUE043091T2 (hu) 2012-12-05 2013-12-03 Immunogén készítmény

Country Status (22)

Country Link
US (2) US9694064B2 (cg-RX-API-DMAC7.html)
EP (2) EP3513806B1 (cg-RX-API-DMAC7.html)
JP (2) JP6290918B2 (cg-RX-API-DMAC7.html)
CN (2) CN112807422A (cg-RX-API-DMAC7.html)
AR (1) AR093712A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013354186A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015012841B1 (cg-RX-API-DMAC7.html)
CA (1) CA2893435C (cg-RX-API-DMAC7.html)
CY (1) CY1121560T1 (cg-RX-API-DMAC7.html)
DK (2) DK3513806T5 (cg-RX-API-DMAC7.html)
ES (2) ES2939307T3 (cg-RX-API-DMAC7.html)
FI (1) FI3513806T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20190711T1 (cg-RX-API-DMAC7.html)
HU (2) HUE061273T2 (cg-RX-API-DMAC7.html)
LT (2) LT3513806T (cg-RX-API-DMAC7.html)
PL (2) PL2928489T3 (cg-RX-API-DMAC7.html)
PT (2) PT2928489T (cg-RX-API-DMAC7.html)
SG (1) SG11201503861UA (cg-RX-API-DMAC7.html)
SI (2) SI2928489T1 (cg-RX-API-DMAC7.html)
TR (1) TR201905272T4 (cg-RX-API-DMAC7.html)
WO (1) WO2014086787A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201503927B (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2283857T3 (da) * 2005-06-27 2019-10-28 Glaxosmithkline Biologicals Sa Vaccinesammensætning omfattende konjugerede native N. Meningitidis kapselpolysaccharider
US9598472B2 (en) 2010-09-03 2017-03-21 Valneva Austria Gmbh Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereof
BR112013027229B1 (pt) 2011-04-22 2020-10-27 Wyeth Llc polipeptídeo imunogênico isolado e seu uso, composição imunogênica e seu uso, célula recombinante ou progênie da mesma, e método de produção de uma toxina de clostridium difficile mutante
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
CN112807422A (zh) * 2012-12-05 2021-05-18 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
PL3160500T3 (pl) * 2014-06-25 2020-02-28 Glaxosmithkline Biologicals S.A. Immunogenna kompozycja clostridium difficile
HUE038212T2 (hu) * 2014-07-25 2018-10-29 Biosynth Srl Többszörös beépített epitópokat kifejezõ molekuláris konstrukt bázikus egységeket tartalmazó glikokonjugátum vakcinák enteropatogén baktériumok által okozott fertõzések elleni szélesspektrumú vakcina elõállításához
WO2016131157A1 (en) 2015-02-19 2016-08-25 Immune Biosolutions Inc Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2017165398A1 (en) 2016-03-21 2017-09-28 Children's Medical Center Corporation Compositions and methods for inhibiting wnt signaling
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CA3056090A1 (en) 2017-03-15 2018-09-20 Novavax, Inc. Methods and compositions for inducing immune responses against clostridium difficile
CN107397956A (zh) * 2017-08-08 2017-11-28 南开大学 一种铜绿假单胞菌外膜蛋白疫苗的制备方法及应用
US12252515B2 (en) 2018-01-16 2025-03-18 Children's Medical Center Corporation Compositions and methods for inhibiting Wnt signaling
GB201804092D0 (en) * 2018-03-14 2018-04-25 Imperial Innovations Ltd Methods and compositions
US10933126B2 (en) 2018-05-03 2021-03-02 The Board Of Regents Of The University Of Oklahoma Clostridium difficile immunogenic compositions and methods of use
MX2021014097A (es) * 2019-05-21 2022-03-11 Univ California Composiciones de vacunas para clostridium difficile.
US20230218735A1 (en) * 2020-06-19 2023-07-13 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
US20240189410A1 (en) * 2022-12-13 2024-06-13 Pfizer Inc. Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
EP4658302A1 (en) 2023-02-02 2025-12-10 GlaxoSmithKline Biologicals S.A. Immunogenic composition

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
WO1988009797A1 (en) 1987-06-05 1988-12-15 The United States Of America, As Represented By Th Autocrine motility factors in cancer diagnosis and management
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ES2068989T3 (es) 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoles como adyuvante en vacunas.
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
EP0812593B8 (en) 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JP2002514886A (ja) 1994-10-24 2002-05-21 プロメガ コーポレーション クロストリジウム・ディフィシル疾患の治療及び予防のためのワクチン及び抗トキシン
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE69829400T2 (de) 1997-10-20 2006-04-13 Acambis, Inc., Cambridge Passive immunisierung gegen durch clostridium difficile verursachte krankheit
US6733760B1 (en) * 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
EP1169456B1 (en) 1999-04-09 2012-07-11 Intercell USA, Inc. Recombinant production of Clostridium difficile Toxin A or Toxin B
WO2001073030A2 (en) 2000-03-28 2001-10-04 Diadexus, Inc. Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
US20090028903A1 (en) * 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0525321D0 (en) * 2005-12-13 2006-01-18 Glaxosmithkline Biolog Sa Novel compositions
CN101522218B (zh) * 2006-10-12 2012-09-26 葛兰素史密丝克莱恩生物有限公司 包含水包油乳液佐剂的疫苗
GB0711858D0 (en) 2007-06-19 2007-07-25 Glaxosmithkline Biolog Sa Vaccine
KR20160005378A (ko) 2007-09-14 2016-01-14 사노피 파스테르 바이오로직스, 엘엘씨 클로스트리듐 디피실리 톡소이드 ａ 및 ｂ를 포함하는 약학적 조성물
HUE026586T2 (hu) * 2008-04-16 2016-06-28 Glaxosmithkline Biologicals Sa Vakcina
US20120020996A1 (en) * 2008-08-06 2012-01-26 Jonathan Lewis Telfer Vaccines against clostridium difficile and methods of use
US9598472B2 (en) 2010-09-03 2017-03-21 Valneva Austria Gmbh Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereof
DK2714910T3 (en) * 2011-05-27 2018-02-05 Glaxosmithkline Biologicals Sa Immunogenic composition
CN112807422A (zh) * 2012-12-05 2021-05-18 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物

Also Published As

Publication number Publication date
LT3513806T (lt) 2023-04-11
TR201905272T4 (tr) 2019-05-21
US20170340719A1 (en) 2017-11-30
PT3513806T (pt) 2023-03-02
LT2928489T (lt) 2019-04-10
JP2018104446A (ja) 2018-07-05
US9694064B2 (en) 2017-07-04
CA2893435C (en) 2024-11-12
ZA201503927B (en) 2017-11-29
EP3513806B1 (en) 2023-01-25
US10130694B2 (en) 2018-11-20
BR112015012841B1 (pt) 2022-05-03
HRP20230359T1 (hr) 2023-06-09
US20150313984A1 (en) 2015-11-05
EP2928489A1 (en) 2015-10-14
CA2893435A1 (en) 2014-06-12
FI3513806T3 (fi) 2023-04-26
JP6626521B2 (ja) 2019-12-25
ES2721930T3 (es) 2019-08-06
HRP20190711T1 (hr) 2019-05-31
HUE043091T2 (hu) 2019-08-28
EP2928489B1 (en) 2019-02-27
PL2928489T3 (pl) 2019-07-31
DK3513806T3 (da) 2023-02-27
CN112807422A (zh) 2021-05-18
JP2016502551A (ja) 2016-01-28
CY1121560T1 (el) 2020-05-29
DK2928489T3 (en) 2019-04-23
PL3513806T3 (pl) 2023-05-15
BR112015012841A2 (pt) 2017-09-26
ES2939307T3 (es) 2023-04-20
CN104884081A (zh) 2015-09-02
AU2013354186A1 (en) 2014-06-12
SI3513806T1 (sl) 2023-04-28
DK3513806T5 (da) 2024-09-02
JP6290918B2 (ja) 2018-03-07
SI2928489T1 (sl) 2019-05-31
WO2014086787A1 (en) 2014-06-12
PT2928489T (pt) 2019-05-28
AR093712A1 (es) 2015-06-17
SG11201503861UA (en) 2015-06-29
EP3513806A1 (en) 2019-07-24

Similar Documents

Publication Publication Date Title
HUE061273T2 (hu) Immunogén készítmény
SI3725778T1 (sl) Formulacije enzalutamida
HRP20180870T1 (hr) Antitijelo-lijek konjugat
IL235890A0 (en) vaccine
EP3818947C0 (en) Fenestrated implant
HUE037048T2 (hu) Eljárások 4-cikloalkiloxibenzolszulfonamidok elõállítására
EP2902071A4 (en) INTERCONNECTS
DK2841054T4 (da) Injicerbart præparat
SMT201700110B (it) Composizione immunogena
FR2998638B1 (fr) Raccord
DK2668967T3 (da) Implantat
EP2876161A4 (en) VACCINE
GB201223386D0 (en) Vaccine
BR112014005756A2 (pt) vacina
EP2829281A4 (en) VACCINE AGAINST LIPOPOLYSACCHARIDES (LPS)
IL231660A0 (en) Composition
EP2931176A4 (en) Medical sling
PL2863921T3 (pl) Koniugat polimer-nlpz
PL2908835T3 (pl) Stabilne formulacje
HRP20181667T1 (hr) Pripravak
EP2804626A4 (en) VACCINE BASED ON AUTOLOGOUS CANCER CELLS
EP2814560A4 (en) INTERCONNECTS
EP2822599A4 (en) VACCINE FORMULATION
HRP20190033T1 (hr) Pripravak
GB201210226D0 (en) Vaccine